NCTR changes leaders
This article was originally published in The Tan Sheet
Executive SummaryWilliam Slikker, Jr. is the new acting director of FDA's National Center for Toxicological Research, the agency announces Jan. 3. He replaces Don Casciano, who served as NCTR director for six years and will move to the private sector. Slikker, who is a member of the Teratology Society and the Society of Toxicology, is an adjunct professor in the the Department of Pharmacology & Toxicology at the University of Arkansas, and as associate editor of the journals NeuroToxicology and Toxicological Sciences. He most recently served as NCTR's Deputy Center Director for Research...
You may also be interested in...
New research links the use of stents and balloons coated with the drug paclitaxel to an increased risk of lower-leg amputation shortly following surgery. The study was conducted by Greek researcher Konstantinos Katsanos, who previously found an increased mortality risk in paclitaxel-treated patients.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
Smith & Nephew has acquired Tusker Medical for an undisclosed price. The acquisition comes just months after Tusker’s Tula system was approved by the FDA as a breakthrough device.